You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the P…

Share

Article menu
Download PDFPDF
Oral Communication 1 – Gynaecological Cancer
Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the P…
(Your Name) has forwarded a page to you from International Journal of Gynecologic Cancer
(Your Name) thought you would like to see this page from the International Journal of Gynecologic Cancer web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.